Acquisition of Doxorubicin Resistance Induces Breast Cancer Cell Migration and Epithelial-Mesenchymal Transition that are Reversed by Shikonin-Metformin Synergy Dox resistance and BC cell migration
Abstract
Background: Drug resistance is a major challenge in cancer chemotherapy.
Methods: By adopting an appropriately timed strategy, we generated MCF-7 cell sublines resistant to serial doses of doxorubicin (DOX). Our higher-dose sublines showed more stability in resistance and were, therefore, subjected to further analyses. We tested the consistency of drug resistance by comparing sublines with control groups for growth and migration capacities. Molecular analyses monitored expression changes, CD44/CD24 ratios, and DOX binding to key molecules. The reverting impact of shikonin (SHKN) and metformin (MTFN) on DOX resistance was examined.
Results. The resistant sublines grew parallel to or even faster than WT MCF-7 cells and showed a larger and more rounded morphology. The consistency of their drug resistance and invasive potential was demonstrated over time using serial doses of DOX. Real-time PCR revealed upregulation of genes involved in cell growth and survival, drug resistance, migration/invasion, and epithelial-mesenchymal transition and, conversely, downregulation of pro-apoptotic, anti-chemoresistance, and tumor suppressor genes. SHKN-MTFN co-treated resistant cells showed significantly lower CD44/CD24 ratios, less aggressiveness, and reduced survival and migration rates but enhanced apoptosis. SHKN’s affinity to CYP1A and TOP2A demonstrated the importance of these interactions and the compounds’ capacity to compete with DOX.
Conclusion: Acquisition of DOX resistance increases tumorigenic properties of cancer cells, whereas synergy between selective anti-tumorigenic compounds re-sensitizes resistant cells by reverting cellular pathways that favor or follow resistance. Our findings suggest that this reversal is supported by competing reactions that deprive DOX of binding to its target molecules.
Full text article
References
Vasan N, Baselga J, Hyman DM. A view on drug resistance in cancer. Nature 2019;575:299–309. doi:10.1038/s41586-019-1730-1.
Houseman G. Byler S, Heerboth S, Lapinska K, Longacre M, Snyder N, Sarkar S. Drug resistance in cancer: an overview. Cancers (Basel). 2014;6(3):1769-92. doi: 10.3390/cancers6031769.
Barrett-Lee PJ, Dixon JM, Farrell C, Jones A, Leonard R, Murray N, Palmieri C, Plummer CJ, Stanley A, Verrill MW. Expert opinion on the use of anthracyclines in patients with advanced breast cancer at cardiac risk. Ann Oncol. 2009;20(5):816-27. doi: 10.1093/annonc/mdn728.
“Doxorubicin Hydrochloride”. The American Society of Health-System Pharmacists. Doxorubicin Hydrochloride Monograph for Professionals-Drugs.com (archive.org). Retrieved 27 March 2022.
Thorn CF, Oshiro C, Marsh S, Hernandez-Boussard T, McLeod H, Klein TE, Altman RB. Doxorubicin pathways: pharmacodynamics and adverse effects. Pharmacogenet Genomics. 2011;21(7):440-6. doi: 10.1097/FPC.0b013e32833ffb56.
Early Breast Cancer Trialists’ Collaborative Group (EBCTCG). Early Breast Cancer Trialists’ Collaborative Group (EBCTCG). Anthracycline-containing and taxane-containing chemotherapy for early-stage operable breast cancer: a patient-level meta-analysis of 100 000 women from 86 randomised trials. Lancet. 2023;401(10384):1277-1292. doi: 10.1016/S0140-6736(23)00285-4.
Christowitz C, Davis T, Isaacs A, van Niekerk G, Hattingh S, Engelbrecht AM. Mechanisms of doxorubicin-induced drug resistance and drug resistant tumour growth in a murine breast tumour model. BMC Cancer. 2019;19(1):757. doi: 10.1186/s12885-019-5939-z.
Cox J, Weinman S. Mechanisms of doxorubicin resistance in hepatocellular carcinoma. Hepat Oncol. 2016;3(1):57-59. doi:10.2217/hep.15.41.
Solazzo M, Fantappie O, D’Amico M et al. Mitochondrial expression and functional activity of breast cancer resistance protein in different multiple drug-resistant cell lines. Cancer Res. 2009;69:7235–7242. doi: 10.1158/0008-5472.CAN-08-4315.
Zhang J, Wang Y, Zhen P et al. Genome-wide analysis of miRNA signature differentially expressed in doxorubicin-resistant and parental human hepatocellular carcinoma cell lines. PLoS ONE; 20138(1): e54111. doi: 10.1371/journal.pone.0054111.
Kubiliūtė R, Šulskytė I, Daniūnaitė K, Daugelavičius R, Jarmalaitė S. Molecular features of doxorubicin-resistance development in colorectal cancer CX-1 cell line. Medicina (Kaunas). 2016;52(5):298-306. doi: 10.1016/j.medici.2016.09.003.
AbuHammad S, Zihlif M. Gene expression alterations in doxorubicin resistant MCF7 breast cancer cell line. Genomics. 2013;101(4):213-20. doi: 10.1016/j.ygeno.2012.11.009.
Gardaneh M, Shojaei S, Kaviani A, Behnam B GDNF induces RET-SRC-HER2-dependent growth in trastuzumab-sensitive but SRC-independent growth in resistant breast tumor cells. Breast Cancer Res Treat. Breast Cancer Res Treat. 2017;162(2):231-241. doi: 10.1007/s10549-016-4078-3.
Livak KJ, Schmittgen TD (2001) Analysis of relative gene expression data using real-time quantitative PCR and the 2−ΔΔCT method. Methods;25(4):402-8.doi: 10.1006/meth.2001.1262.
Rostamian Tabari A, Gavidel P, Sabouni F, Gardaneh M (2022) Synergy between sublethal doses of shikonin and metformin fully inhibits breast cancer cell migration and reverses epithelial-mesenchymal transition. Mol Biol Rep. 2022:49(6):4307-4319. doi: 10.1007/s11033-022-07265-9. Epub 2022 May 7.
Dagogo-Jack, I., Shaw, A. Tumour heterogeneity and resistance to cancer therapies. Nat Rev Clin Oncol;15(2):81–94. Doi:10.1038/nrclinonc.2017.166.
Yang CL, Jiang FQ, Xu F, Jiang GX. ADAM10 overexpression confers resistance to doxorubicin-induced apoptosis in hepatocellular carcinoma. Tumour Biol. 2012;33(5):1535-41. doi: 10.1007/s13277-012-0405-4.
Chen JM, Bai JY, Yang KX. Effect of resveratrol on doxorubicin resistance in breast neoplasm cells by modulating PI3K/Akt signaling pathway. IUBMB Life. 2018;70(6):491-500. doi: 10.1002/iub.1749.
Aminipour Z, Khorshid M, Keshvari H, Bonakdar S, Wagner P, Van der Bruggen B. Passive permeability assay of doxorubicin through model cell membranes under cancerous and normal membrane potential conditions. Eur J Pharm Biopharm. 2020;146:133-142. doi: 10.1016/j.ejpb.2019.10.011.
Forrest RA, Swift LP, Rephaeli A, Nudelman A, Kimura K, Phillips DR, Cutts SM. Activation of DNA damage response pathways as a consequence of anthracycline-DNA adduct formation. Biochem Pharmacol. 2012;15;83(12):1602-12. doi: 10.1016/j.bcp.2012.02.026.
Lu L, Ju F, Zhao H, Ma X. MicroRNA-134 modulates resistance to doxorubicin in human breast cancer cells by downregulating ABCC1. Biotechnol Lett. 2015;37(12):2387-94. doi: 10.1007/s10529-015-1941-y.
Munoz M, Henderson M, Haber M, Norris M. Role of the MRP1/ABCC1 multidrug transporter protein in cancer. IUBMB Life. 2007;59(12):752-7. doi: 10.1080/15216540701736285.
Bonhoure E, Pchejetski D, Aouali N, Morjani H, Levade T, KohamaT, Cuvillier O. Overcoming MDR-associated chemoresistance in HL-60 acute myeloid leukemia cells by targeting sphingosine kinase-1. Leukemia. 2006;20(1):95-102. doi: 10.1038/sj.leu.2404023.
Angelini A, Ciofani G, Baccante G, Di Febbo C, Carmine DI, Cuccurullo F, Porreca E. Modulatory effects of heparin on cellular accumulation and cytotoxicity of doxorubicin in MRP1-overexpressing HL60/doxo cells. Anticancer Res 2007;27(1A):351-5.
Li Y, Ye Y, Feng B, Qi Y. Long Noncoding RNA lncARSR Promotes Doxorubicin Resistance in Hepatocellular Carcinoma via Modulating PTEN-PI3K/Akt Pathway. J Cell Biochem. 2017;118(12):4498-4507. doi: 10.1002/jcb.26107.
Jung KA, Choi BH, Kwak MK. The c-MET/PI3K signaling is associated with cancer resistance to doxorubicin and photodynamic therapy by elevating BCRP/ABCG2 expression. Mol Pharmacol. 2015;87(3):465-76. doi: 10.1124/mol.114.096065.
Ugarenko M, Nudelman A, Rephaeli A, Kimura K, Phillips DR, Cutts SM. ABT-737 overcomes Bcl-2 mediated resistance to doxorubicin-DNA adducts. Biochem Pharmacol. 2010;79(3):339-49. doi: 10.1016/j.bcp.2009.09.004.
van Oosterwijk JG, Herpers B, Meijer D, Briaire-de Bruijn IH, Cleton-Jansen AM, Gelderblom H, van de Water B, Bovée JV. Restoration of chemosensitivity for doxorubicin and cisplatin in chondrosarcoma in vitro: BCL-2 family members cause chemoresistance. Ann Oncol. 2012;23(6):1617-26. doi: 10.1093/annonc/mdr512.
Sun W, Chen X, Xie C, Wang Y, Lin L, Zhu K, Shuai X. Co-Delivery of Doxorubicin and Anti-BCL-2 siRNA by pH-Responsive Polymeric Vector to Overcome Drug Resistance in In Vitro and In Vivo HepG2 Hepatoma Model. Biomacromolecules. 2018;19(6):2248-2256. doi: 10.1021/acs.biomac.8b00272.
Zhao Y, Zhang CL, Zeng BF, Wu XS, Gao TT, Oda Y. Enhanced chemosensitivity of drug-resistant osteosarcoma cells by lentivirus-mediated Bcl-2 silencing. Biochem Biophys Res Commun. 2009;390(3):642-7. doi: 10.1016/j.bbrc.2009.10.020.
Lovitt CJ, Shelper TB, Avery VM. Doxorubicin resistance in breast cancer cells is mediated by extracellular matrix proteins. BMC Cancer. 2018;18(1):41. doi:10.1186/s12885-017-3953-6.
Shen CJ, Kuo YL, Chen CC, Chen MJ, Cheng YM. MMP1 expression is activated by Slug and enhances multi-drug resistance (MDR) in breast cancer. PLoS One. 2017;12(3):e0174487. doi: 10.1371/journal.pone.0174487.
Yang X, Shang P, Yu B, Jin Q, Liao J, Wang L, Ji J, Guo X. Combination therapy with miR34a and doxorubicin synergistically inhibits Dox-resistant breast cancer progression via down-regulation of Snail through suppressing Notch/NF-κB and RAS/RAF/MEK/ERK signaling pathway. Acta Pharm Sin B. 2021;11(9):2819-2834. doi: 10.1016/j.apsb.2021.06.003.
Gariboldi MB, Ravizza R, Molteni R, Osella D, Gabano E, Monti E. Inhibition of Stat3 increases doxorubicin sensitivity in a human metastatic breast cancer cell line. Cancer Lett. 2007;258(2):181-8. doi: 10.1016/j.canlet.2007.08.019.
Polyak K, Weinberg RA. Transitions between epithelial and mesenchymal states: acquisition of malignant and stem cell traits. Nat Rev Cancer. 2009;9(4):265-73. doi: 10.1038/nrc2620.
Wan X, Hou J, Liu S, Zhang Y, Li W, Zhang Y, Ding Y. Estrogen Receptor α Mediates Doxorubicin Sensitivity in Breast Cancer Cells by Regulating E-Cadherin. Front Cell Dev Biol. 2021 Feb 4;9:583572. doi: 10.3389/fcell.2021.583572.
Hientz K, Mohr A, Bhakta-Guha D, Efferth T. The role of p53 in cancer drug resistance and targeted chemotherapy. Oncotarget. 2017;8(5):8921-8946. doi:10.18632/oncotarget.13475.
Zuryń A, Litwiniec A, Klimaszewska-Wiśniewska A, Nowak JM, Gackowska L, Myśliwiec BJ, Pawlik A, Grzanka A. Expression of cyclin D1 after treatment with doxorubicin in the HL-60 cell line. Cell Biol Int. 2014;38(7):857-67. doi: 10.1002/cbin.10290.
Tarasewicz E, Hamdan R, Straehla J, Hardy A, Nunez O, Zelivianski S, Dokic D, Jeruss JS. CDK4 inhibition and doxorubicin mediate breast cancer cell apoptosis through Smad3 and survivin. Cancer Biol Ther. 2014;15(10):1301-11. doi: 10.4161/cbt.29693.
Li J, Liu W, Hao H, Wang Q and Xue L: Rapamycin enhanced the antitumor effects of doxorubicin in myelogenous leukemia K562 cells by downregulating the mTOR/p70S6K pathway. Oncol Lett. 2019;18(3):2694-2703. doi: 10.3892/ol.2019.10589.
Denard B, Lee C, Ye J. Doxorubicin blocks proliferation of cancer cells through proteolytic activation of CREB3L1. Elife. 2012;1:e00090. doi: 10.7554/eLife.00090.
Huilgol D, Venkataramani P, Nandi S, Bhattacharjee S. Transcription Factors That Govern Development and Disease: An Achilles Heel in Cancer. Genes (Basel). 2019;10(10):794. doi: 10.3390/genes10100794.
Authors
Copyright (c) 2024 Archives of Breast Cancer
This work is licensed under a Creative Commons Attribution-NonCommercial 4.0 International License.
Copyright©. This is an open-access article distributed under the terms of the Creative Commons Attribution-Non-Commercial 4.0 International License, which permits copy and redistribution of the material in any medium or format or adapt, remix, transform, and build upon the material for any purpose, except for commercial purposes.